Figure 2

The inhibitory effect of the CTCM on OVA-induced R _L increase is mediated by the β-adrenergic receptor. OVA-sensitized guinea pigs were pre-treated with the β-adrenoceptor antagonist propranolol, followed by CTCM inhalation or no CTCM inhalation before OVA challenge. Comparison between the SGP_O, SGP_MO and SGP_AMO groups of sensitized animals in a 7-hr period (repeated measures ANOVA with a Mauchly post-hoc test, SGP_AMO vs. SGP_MO; **P <0.01). Each point represents the mean of the data from 10-12 animals and the vertical bars represent the standard deviation. SGP_O: sensitized guinea pigs challenged with OVA by nebulization; SGP_MO: sensitized guinea pigs treated with 0.06 g/ml nebulized CTCM for 5 min, followed by OVA challenge by nebulization (at 5 min post-CTCM nebulization); SGP_AMO: sensitized guinea pigs pre-treated with β-adrenoceptor antagonist propranolol (1 mg/kg i.v.) for 3 min before treating with nebulized 0.06 g/ml CTCM for 5 min, and finally challenged by OVA by nebulization (at 5 min post-CTCM).